While no KDM5C-specific inhibitor exists, pan-KDM5 inhibitors (KDM5i) are available and have been used in clinical trials for the treatment of cancer and hepatitis B (30, 31). The gene discussed is KDM5C; the disease is hepatitis B virus infection.